Model-informed Drug Discovery & Development (MID3) has been shown to be particularly useful in the drug development process and delivery of new therapies.
Using findings from the article Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives (CPT Pharmacometrics Syst. Pharmacol., 8: 87-96) as a reference point, a panel of up to three experts share their experience and insights surrounding model-based drug discovery and knowledge management.
They communicate recent advancements in methodology and explore what strides are necessary in order to achieve more predictable, cost-effective, and desired outcomes in the field of drug discovery and development.
Sponsored by John Wiley & Sons, Inc. and Research Solutions, Inc.
Learn More about Research Solutions:
source
